首页> 美国卫生研究院文献>Blood >Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
【2h】

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

机译:移植前条件疗法强度对异基因造血干细胞移植前侵袭性曲霉病患者的影响:对欧洲血液和骨髓移植小组传染病工作组的回顾性调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this retrospective study, we analyzed the outcomes of 129 patients who underwent an allogeneic hematopoietic stem cell transplantation (allo-HSCT) and had a history of probable or proven invasive aspergillosis (IA), of whom 57 (44%) received a reduced-intensity conditioning (RIC). Overall, 27 patients with IA progressed after the allo-HSCT (cumulative incidence [CumInc] at 2 years, 22%). The variables that increased the 2-year CumInc of IA progression were (1) longer duration of neutropenia after transplantation; (2) advanced status of the underlying disease; and (3) less than 6 weeks from start of systemic anti-Aspergillus therapy and the allo-HSCT. In addition, (4) conventional myeloablative conditioning increased the risk of progression early after transplantation (before day 30) only, while 3 variables increased the risk beyond day 30 were (5) cytomegalovirus disease; (6) bone marrow or cord blood as source of stem cells; and (7) grades II to IV acute graft-versus-host disease (GVHD). A risk model for progression was generated, defined as low (0-1 risk factors, 6% incidence), intermediate (2-3 risk factors, 27% incidence), or high risk (≥ 3 risk factors, 72% incidence [P < .001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT.
机译:在这项回顾性研究中,我们分析了接受同种异体造血干细胞移植(allo-HSCT)并有可能或经证实的浸润性曲霉病(IA)病史的129例患者的结局,其中57例(44%)的患者强度调节(RIC)。总的来说,27例IA患者在进行allo-HSCT后进展(2年累计发生率[CumInc],占22%)。导致IA进展的2年CumInc增加的变量是:(1)移植后中性粒细胞减少的持续时间更长; (2)基础疾病的晚期状态; (3)从全身抗曲霉菌疗法和allo-HSCT开始治疗后不到6周。此外,(4)传统的清髓性调理仅增加了移植后早期(第30天之前)进展的风险,而3个变量增加了超过30天的风险是(5)巨细胞病毒病; (6)以骨髓或脐带血为干细胞; (7)II至IV级急性移植物抗宿主病(GVHD)。生成了进展风险模型,定义为低(0-1个危险因素,占6%的发生率),中级(2-3个危险因素,占27%的发生率)或高风险(≥3个危险因素,占72%的发生率[P <.001])。这些发现可能有助于解释和设计异基因HSCT后IA继发预防的未来研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号